Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• The discovery of the Janus-associated kinase 2 (JAK2) V617F mutation has significantly advanced research in Philadelphia-negative myeloproliferative neoplasms (MPNs).
• Despite extensive research identifying numerous therapeutic targets, the clinical options for MPNs remain limited, with few new drugs approved in recent decades.
• Current treatment strategies primarily focus on managing vascular complications and long-term risks like transformation to myelodysplastic syndrome or acute leukemia.

Purpose of the Study:

• To review the progress in understanding and treating Philadelphia-negative myeloproliferative neoplasms (MPNs) following the discovery of the JAK2 V617F mutation.
• To assess the current therapeutic landscape for MPNs, including approved drugs, investigational therapies, and the role of conventional treatments.
• To highlight the unmet needs in MPN treatment, particularly the lack of disease-modifying agents and the limitations of current curative approaches.

Main Methods:

• Literature review of basic and clinical research on JAK2 V617F mutation and MPNs.
• Analysis of approved therapies and investigational treatments for myeloproliferative neoplasms.
• Evaluation of current treatment strategies based on risk stratification and long-term outcomes.

Main Results:

• While the JAK2 V617F mutation discovery has driven research, only one new drug, ruxolitinib, has been approved for MPNs in 40 years.
• Conventional therapies, including cytotoxic agents and anagrelide, remain mainstays, with the role of interferon alfa still under investigation.
• Allogeneic stem cell transplantation is the only curative option, reserved for high-risk patients or those with disease transformation.

Conclusions:

• The therapeutic armamentarium for MPNs is still limited, necessitating the development of novel disease-modifying therapies.
• Current treatment strategies do not adequately address the long-term risks of transformation to more aggressive hematologic malignancies.
• Further research is crucial to identify effective treatments that can alter the natural history of MPNs and improve patient outcomes.